Next Article in Journal
Unlocking the Door to Neuronal Woes in Alzheimer’s Disease: Aβ and Mitochondrial Permeability Transition Pore
Next Article in Special Issue
Difficulties in Treatment and Management of Epilepsy and Challenges in New Drug Development
Previous Article in Journal
A Review of Topical Diclofenac Use in Musculoskeletal Disease
Previous Article in Special Issue
Natural Products in Epilepsy—the Present Situation and Perspectives for the Future
A comment was published on 17 December 2010, see Pharmaceuticals 2010, 3(12), 3629-3632.

Pharmaceuticals 2010, 3(6), 1909-1935; doi:10.3390/ph3061909
Review

Therapeutic Drug Monitoring of the Newer Anti-Epilepsy Medications

Received: 26 April 2010; in revised form: 11 May 2010 / Accepted: 9 June 2010 / Published: 11 June 2010
(This article belongs to the Special Issue Antiepileptic Drugs)
View Full-Text   |   Download PDF [293 KB, uploaded 14 June 2010]   |   Browse Figure
Abstract: In the past twenty years, 14 new antiepileptic drugs have been approved for use in the United States and/or Europe. These drugs are eslicarbazepine acetate, felbamate, gabapentin, lacosamide, lamotrigine, levetiracetam, oxcarbazepine, pregabalin, rufinamide, stiripentol, tiagabine, topiramate, vigabatrin and zonisamide. In general, the clinical utility of therapeutic drug monitoring has not been established in clinical trials for these new anticonvulsants, and clear guidelines for drug monitoring have yet to be defined. The antiepileptic drugs with the strongest justifications for drug monitoring are lamotrigine, oxcarbazepine, stiripentol, and zonisamide. Stiripentol and tiagabine are strongly protein bound and are candidates for free drug monitoring. Therapeutic drug monitoring has lower utility for gabapentin, pregabalin, and vigabatrin. Measurement of salivary drug concentrations has potential utility for therapeutic drug monitoring of lamotrigine, levetiracetam, and topiramate. Therapeutic drug monitoring of the new antiepileptic drugs will be discussed in managing patients with epilepsy.
Keywords: anticonvulsants; drug monitoring; drug toxicity; epilepsy; seizures anticonvulsants; drug monitoring; drug toxicity; epilepsy; seizures
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Krasowski, M.D. Therapeutic Drug Monitoring of the Newer Anti-Epilepsy Medications. Pharmaceuticals 2010, 3, 1909-1935.

AMA Style

Krasowski MD. Therapeutic Drug Monitoring of the Newer Anti-Epilepsy Medications. Pharmaceuticals. 2010; 3(6):1909-1935.

Chicago/Turabian Style

Krasowski, Matthew D. 2010. "Therapeutic Drug Monitoring of the Newer Anti-Epilepsy Medications." Pharmaceuticals 3, no. 6: 1909-1935.


Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert